Omalizumab may not inhibit mast cell and basophil activation in vitro
暂无分享,去创建一个
M. Maurer | M. Church | M. Metz | J. Gericke | T. Ohanyan
[1] M. Maurer,et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. , 2015, The Journal of allergy and clinical immunology.
[2] T. Zuberbier,et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.
[3] M. Maurer,et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.
[4] T. Casale,et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.
[5] M. Maurer,et al. Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1‐antihistamines , 2012, Experimental dermatology.
[6] M. Vogel,et al. Inhibition of ongoing allergic reactions using a novel anti‐IgE DARPin‐Fc fusion protein , 2011, Allergy.
[7] P. Martus,et al. IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria? , 2011, PloS one.
[8] J. Douglass,et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient , 2009, Allergy.
[9] C. Bindslev‐Jensen,et al. Peanut cross‐reacting allergens in seeds and sprouts of a range of legumes , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[10] R. Katz,et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. , 2008, Allergy and asthma proceedings.
[11] T. Zuberbier,et al. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. , 2007, The Journal of allergy and clinical immunology.
[12] S. Saini,et al. Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticaria , 2007 .
[13] S. Saini,et al. Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria. , 2007, The Journal of allergy and clinical immunology.
[14] T. Kawakami,et al. Mast Cell Survival and Activation by IgE in the Absence of Antigen: A Consideration of the Biologic Mechanisms and Relevance1 , 2005, The Journal of Immunology.
[15] C. Grattan,et al. Validation of basophil histamine release against the autologous serum skin test and outcome of serum‐induced basophil histamine release studies in a large population of chronic urticaria patients , 2005, Allergy.
[16] Toshiaki Kawakami,et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcεRI , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] C. Grattan,et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] W. Fridman,et al. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. , 1995, The Journal of clinical investigation.